KEGG   DRUG: D03455Help
Entry
D03455                      Drug                                   
Name
Cetuximab (genetical recombination) (JAN);
Cetuximab (USAN/INN);
Erbitux (TN)
Product
Activity
Treatment of EGF receptor-expressing cancers [monoclonal antibody] [DS:H00016 H00020 H00054 H00055]
Remark
Therapeutic category: 
ATC code: 
Comment
monoclonal antibody
Target
Epidermal Growth Factor Receptor (EGFR) [HSA:1956] [KO:K04361]
  Pathway
hsa04010  MAPK signaling pathway
hsa04012  ErbB signaling pathway
hsa04020  Calcium signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa05200  Pathways in cancer  
 
Interaction
Genomic biomarker: EGFR [HSA:1956] positive, KRAS [HSA:3845] mutation negative
Drug interaction
Structure map
Antineoplastics - protein kinases inhibitors
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D03455  Cetuximab (genetical recombination) (JAN); Cetuximab (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC06 Cetuximab
      D03455  Cetuximab (genetical recombination) (JAN); Cetuximab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Receptor tyrosine kinase
   RTK class I (EGF receptor family)
    epidermal growth factor receptor (EGFR) [HSA:1956] [KO:K04361]
     Cetuximab [ATC:L01XC06]
      D03455  Cetuximab (genetical recombination) (JAN); Cetuximab (USAN/INN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Cetuximab [ATC:L01XC06]
    D03455  Cetuximab (genetical recombination) (JAN); Cetuximab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
205923-56-4
PubChem: 
DrugBank: 
NIKKAJI: 

» Japanese version   » Back
DBGET integrated database retrieval system